Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Flatt

Showing results (71-80 of 325) with videos related to

Pageof 33
Sort By:
Diabetes, Obesity & Metabolism|June 9, 2021
Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed miceShruti Mohan, Peter R Flatt, Nigel Irwin, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Biological Chemistry|August 10, 2020
Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytesAndrew English, Sarah L Craig, Peter R Flatt, et al.
Plos One|June 27, 2014
Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stressSrividya Vasu, R Charlotte Moffett, Bernard Thorens, et al.
Peptides|December 3, 2021
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A reviewJ Michael Conlon, Finbarr P M O'Harte, Peter R Flatt
Neuropeptides|November 11, 2003
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?Victor A Gault, Finbarr P M O'Harte, Peter R Flatt
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
The Journal of Endocrinology|October 4, 2007
Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell lineAoife Kiely, Neville H McClenaghan, Peter R Flatt, et al.
Reproductive Biology|June 21, 2023
Disturbed ovarian morphology, oestrous cycling and fertility of high fat fed rats are linked to alterations of incretin receptor expressionDawood Khan, Ananyaa Sridhar, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Pageof 33

Showing results (71-80 of 325) with videos related to

Sort By:
Pageof 33
Diabetes, Obesity & Metabolism|June 9, 2021
Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed miceShruti Mohan, Peter R Flatt, Nigel Irwin, et al.
The Journal of Endocrinology|January 25, 2020
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetesNeil Tanday, Peter R Flatt, Nigel Irwin, et al.
Biological Chemistry|August 10, 2020
Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytesAndrew English, Sarah L Craig, Peter R Flatt, et al.
Plos One|June 27, 2014
Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stressSrividya Vasu, R Charlotte Moffett, Bernard Thorens, et al.
Peptides|December 3, 2021
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A reviewJ Michael Conlon, Finbarr P M O'Harte, Peter R Flatt
Neuropeptides|November 11, 2003
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?Victor A Gault, Finbarr P M O'Harte, Peter R Flatt
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
The Journal of Endocrinology|October 4, 2007
Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell lineAoife Kiely, Neville H McClenaghan, Peter R Flatt, et al.
Reproductive Biology|June 21, 2023
Disturbed ovarian morphology, oestrous cycling and fertility of high fat fed rats are linked to alterations of incretin receptor expressionDawood Khan, Ananyaa Sridhar, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Pageof 33